Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.38 USD | +1.26% | +0.09% | -21.99% |
May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.99% | 2.12B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Chardan Adjusts Price Target on Rocket Pharmaceuticals to $63 From $65, Keeps Buy Rating